Literature DB >> 21916749

Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.

Allison K Delong1, Mingham Wu, Diane Bennett, Neil Parkin, Zhijin Wu, Joseph W Hogan, Rami Kantor.   

Abstract

Access to antiretroviral therapy is increasing globally and drug resistance evolution is anticipated. Currently, protease (PR) and reverse transcriptase (RT) sequence generation is increasing, including the use of in-house sequencing assays, and quality assessment prior to sequence analysis is essential. We created a computational HIV PR/RT Sequence Quality Analysis Tool (SQUAT) that runs in the R statistical environment. Sequence quality thresholds are calculated from a large dataset (46,802 PR and 44,432 RT sequences) from the published literature ( http://hivdb.Stanford.edu ). Nucleic acid sequences are read into SQUAT, identified, aligned, and translated. Nucleic acid sequences are flagged if with >five 1-2-base insertions; >one 3-base insertion; >one deletion; >six PR or >18 RT ambiguous bases; >three consecutive PR or >four RT nucleic acid mutations; >zero stop codons; >three PR or >six RT ambiguous amino acids; >three consecutive PR or >four RT amino acid mutations; >zero unique amino acids; or <0.5% or >15% genetic distance from another submitted sequence. Thresholds are user modifiable. SQUAT output includes a summary report with detailed comments for troubleshooting of flagged sequences, histograms of pairwise genetic distances, neighbor joining phylogenetic trees, and aligned nucleic and amino acid sequences. SQUAT is a stand-alone, free, web-independent tool to ensure use of high-quality HIV PR/RT sequences in interpretation and reporting of drug resistance, while increasing awareness and expertise and facilitating troubleshooting of potentially problematic sequences.

Mesh:

Substances:

Year:  2011        PMID: 21916749      PMCID: PMC3399557          DOI: 10.1089/aid.2011.0120

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  37 in total

Review 1.  Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion?

Authors:  M Stürmer; H W Doerr; W Preiser
Journal:  Curr Drug Targets Infect Disord       Date:  2003-12

2.  Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.

Authors:  R A Galli; B Sattha; B Wynhoven; M V O'Shaughnessy; P R Harrigan
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  HIV cohort collaborations: proposal for harmonization of data exchange.

Authors:  Jesper Kjaer; Bruno Ledergerber
Journal:  Antivir Ther       Date:  2004-08

4.  Base-calling of automated sequencer traces using phred. I. Accuracy assessment.

Authors:  B Ewing; L Hillier; M C Wendl; P Green
Journal:  Genome Res       Date:  1998-03       Impact factor: 9.043

5.  Methods for comparing a DNA sequence with a protein sequence.

Authors:  X Huang; J Zhang
Journal:  Comput Appl Biosci       Date:  1996-12

6.  Maintaining the integrity of human immunodeficiency virus sequence databases.

Authors:  G H Learn; B T Korber; B Foley; B H Hahn; S M Wolinsky; J I Mullins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.

Authors:  Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  The prevalence of antiretroviral drug resistance in the United States.

Authors:  Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

10.  Signature pattern analysis: a method for assessing viral sequence relatedness.

Authors:  B Korber; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

View more
  25 in total

1.  Short communication: new HIV infections at Southern New England academic institutions: implications for prevention.

Authors:  Philip A Chan; Shahzeb Kazi; Amaad Rana; Ilyse Blazar; Colette C Dejong; Kenneth H Mayer; Thomas K Huard; Kim Carleton; Fizza Gillani; Nicole Alexander; Zoanne Parillo; Timothy P Flanigan; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-25       Impact factor: 2.205

2.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

Authors:  Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

3.  Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome.

Authors:  Rebecca Reece; Allison Delong; D'Antuono Matthew; Karen Tashima; Rami Kantor
Journal:  J Clin Virol       Date:  2018-05-21       Impact factor: 3.168

4.  High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.

Authors:  Shanmugam Saravanan; Selvamurthi Gomathi; Allison Delong; Bagavathi Kausalya; Sathasivam Sivamalar; Selvamuthu Poongulali; Katherine Brooks; Nagalingeswaran Kumarasamy; Pachamuthu Balakrishnan; Sunil S Solomon; Susan Cu-Uvin; Rami Kantor
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

5.  Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

Authors:  Tanya Rogo; Allison K DeLong; Philip Chan; Rami Kantor
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

6.  Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.

Authors:  Mia Coetzer; Benjamin Westley; Allison Delong; Chhraing Tray; Dim Sophearin; Eric Nerrienet; Leeann Schreier; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-27       Impact factor: 2.205

7.  HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.

Authors:  Rami Kantor; Allison DeLong; Leeann Schreier; Marissa Reitsma; Emanuel Kemboi; Millicent Orido; Salome Obonge; Robert Boinett; Mary Rono; Wilfred Emonyi; Katie Brooks; Mia Coetzer; Nathan Buziba; Joseph Hogan; Lameck Diero
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

8.  Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.

Authors:  Marita Mann; Lameck Diero; Emmanuel Kemboi; Fidelis Mambo; Mary Rono; Wilfred Injera; Allison Delong; Leeann Schreier; Kara W Kaloustian; John Sidle; Nathan Buziba; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

9.  HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.

Authors:  H R Lapointe; W Dong; G Q Lee; D R Bangsberg; J N Martin; A R Mocello; Y Boum; A Karakas; D Kirkby; A F Y Poon; P R Harrigan; C J Brumme
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men.

Authors:  Philip A Chan; Joseph W Hogan; Austin Huang; Allison DeLong; Marco Salemi; Kenneth H Mayer; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.